Anixa Biosciences, Inc.

NASDAQ:ANIX

Biotechnology

Healthcare
$2.71 +3.72%

+$0.10 today

Market cap
$94.21M
Beta
0.60
P/E (TTM)
-9.3
EPS (TTM)
-$0.30
52W Low $2.32High $5.46

Volume 0.29M

Average 0.12M

ANIX EBITDA Margin

EBITDA as a percentage of revenue.

Anixa Biosciences, Inc.NASDAQ: ANIX

EBITDA Margin · Q2 FY2026 · quarter ended Apr 2026

EBITDA Margin not reported for Q2 FY2026

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterApr 2026
—— QoQ
Last fiscal yearOct 2025
—— YoY
LTMApr 2026
—— YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3 years———
5 years——
10 years——

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2023
-4706.7%
Year-over-year change
—

EBITDA Margin vs competitors

How ANIX compares with its peers on the latest reported figures

ANIX Competitors Peer median
EBITDA Margin for ANIX and competitors
Company Period LTM level YoY 3-year change
AGENAgenus Inc.LTM Mar 2026102.6% +184.0 pp+219.6 pp
SPROSpero Therapeutics, Inc.LTM Mar 202627.2% +185.8 pp+103.2 pp
SEERSeer, Inc.LTM Mar 2026-427.9% +95.5 pp+175.4 pp
IRDOpus Genetics, Inc.LTM Mar 2026-874.0% -638.6 pp-384.3 pp
ENTXEntera Bio Ltd.FY2025-27164.3% -21926.2 pp-17559.8 pp
INOInovio Pharmaceuticals, Inc.FY2025-125425.9% -77690.7 pp-122786.1 pp
ANIXAnixa Biosciences, Inc.FY2025— ——
HURATuHURA Biosciences, Inc.FY2025— ——
ABOSAcumen Pharmaceuticals, Inc.FY2025— ——
ACTUActuate Therapeutics IncFY2025— ——
Peer median (excluding ANIX) -650.9%-271.6 pp-140.6 pp

Competitors are the stored peer set for ANIX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Oct 2021
FY2022
Oct 2022
FY2023
Oct 2023
FY2024
Oct 2024
FY2025
Oct 2025
Revenue512K0210K00
Cost of Revenue385K0161K036K
Gross Profit127K049K0(36K)
Gross Margin24.8%—23.3%——
Research & Development6.19M6.7M4.77M6.4M5.07M
Selling, General & Admin7.07M7.17M6.29M7.44M6.63M
Operating Expenses13.26M13.88M11.06M13.83M11.67M
Depreciation & Amortization59.86K42K46K37K36K
EBITDA(13.08M)(13.73M)(9.88M)(12.66M)(10.99M)
EBITDA Margin-2554.9%—-4706.7%——
Operating Income(13.14M)(13.88M)(11.01M)(13.83M)(11.7M)
Operating Margin-2565.6%—-5243.3%——
Interest Income2.32K104K1.08M1.13M673K
Interest Expense322104K000
Other Income / Expenses7.77K104K1.08M1.13M673K
Income Before Tax(13.13M)(13.77M)(9.93M)(12.7M)(11.03M)
Pre-Tax Margin-2564.0%—-4728.6%——
Income Tax Expense00000
Net Income(12.95M)(13.6M)(9.81M)(12.55M)(10.93M)
Net Margin-2528.6%—-4671.9%——
EPS (Basic)(0.45)(0.45)(0.32)(0.39)(0.34)
EPS (Diluted)(0.45)(0.45)(0.32)(0.39)(0.34)
Weighted Avg Shares28.58M30.37M30.98M31.9M32.45M
Weighted Avg Shares (Diluted)28.58M30.37M30.98M31.9M32.45M

Anixa Biosciences, Inc.

NASDAQ:ANIX

Intrinsic Alpha fair value

Locked

Current Price

$2.71

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.